Global Bone Metabolism Tests Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Bone Metabolism Tests Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Market Overview:

The latest research study on the global Bone Metabolism Tests market finds that the global Bone Metabolism Tests market reached a value of USD 875.63 million in 2022. It’s expected that the market will achieve USD 1219.79 million by 2028, exhibiting a CAGR of 5.68% during the forecast period.

Influence of COVID-19 Outbreak on Bone Metabolism Tests Industry Development

It is acknowledged that the COVID-19 pandemic has caused profound disruption to the delivery of healthcare services globally. This has affected the management of many long-term conditions including osteoporosis as resources are diverted to cover urgent care. The global Covid-19 pandemic has greatly impacted the prevention and care of chronic diseases such as osteoporosis.

For the supply chain, the impact of COVID-19 on the bone metabolism test industry will involve all major links and all entities in the industry chain. The company's management efficiency has declined, commuting has been severely hindered, production plans have been severely hindered, network expansion has been delayed, marketing has been delayed, brand adjustments have been forced, market sales have declined, and company and employee revenue have declined. The government has also put forward higher requirements for the production and operation of enterprises.

Due to the epidemic situation, many countries have imposed controls on domestic transportation and the movement of people, and imposed restrictions on imported goods. This has led to various levels of logistics disruption, cargo accumulation and transportation delays. At present, the logistics industry in various countries is recovering operations according to different national policies. It is expected that after the epidemic is further controlled, it will basically return to normal.

Strength

Bone is a relatively active organ that undergoes significant changes compared to other organs in the body. Bone metabolism is associated with diseases that affect bone and mineral metabolism, including various skeletal and soft tissue infections. Generally, these infections can be combined with Paget’s disease of bone, osteoporosis, developmental disorders of bone and hyperparathyroidism. According to the National Osteoporosis Foundation (NOF), about 54 million Americans live with osteoporosis, and approximately one in two women and one in four men ages 50 and older will break a bone due to the condition. With the increasing aging of the population, the prevalence of osteoporosis is on the rise, and it is crucial to enhance the identification of metabolic bone diseases and the early diagnosis and treatment of osteoporosis. The clinical application of biochemical markers of bone metabolism is gradually gaining momentum and plays an important role in the overall management of osteoporosis, with great potential for application. Because more and more people in the world are threatened by bone diseases, the growing market demand will drive the growth of bone metabolism tests.

Weakness

With high technological and regulatory barriers to entry, immunodiagnostics has been a relatively high-margin industry. The development of bone metabolism test reagents involves a number of core technologies such as key raw material screening, biological raw material modification, and immune reaction system design. As a key raw material for immunodiagnostic reagents, bioactive materials directly affect the quality of the products. The search and screening of bioactive materials is one of the key aspects in the development of diagnostic products, and once the bioactive materials are selected and put into production, their related technology and procurement sources are also one of the core secrets of each manufacturer.

Opportunities

The immunodiagnostics industry has an obvious positive feedback effect, where the best companies outperform their competitors in the process of growing bigger through continuous product improvement and iteration, as well as cost control and quality improvement of raw materials. The current industry variable is the value reshaping of the industry chain initiated by the payment side, which in turn stirs up the demand and supply sides. From the investment point of view, as the product has an obvious positive feedback effect, that is, when the technology, product and market continue to surpass the rivals and reach a certain level, the brand has a greater stickiness.

Region Overview:

From 2022-2027, Asia Pacific is estimated to witness robust growth prospects.

Company Overview:

The major players operating in the Bone Metabolism Tests market include Roche，Siemens Healthineers，Abbott，Beckman Coulter and DiaSorin, etc. Among which, Company1 ranked top in terms of sales and revenue in 2022.

Roche is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Siemens Healthineers is a Germany-based company that supplies technology to the healthcare industry. The Company offers a wide range of products and services in the fields of diagnostic and therapeutic imaging, laboratory and point of care diagnostics, and molecular medicine. It provides medical technology and software solutions, as well as clinical consulting services. Additionally, the Company is developing its digital health and enterprise services through expanding precision medicine, transforming care delivery, improving patient experience, and digitalizing healthcare to enable healthcare providers to increase value.

Segmentation Overview:

Among different product types, CLIA segment is anticipated to contribute the largest market share in 2027.

The enzyme-linked immunosorbent assay (ELISA) is an immunological assay commonly used to measure antibodies, antigens, proteins and glycoproteins in biological samples.

Chemiluminescence immunoassay (CLIA) is an assay that combines chemiluminescence technique with immunochemical reactions. CLIA utilize chemical probes which could generate light emission through chemical reaction to label the antibody.

Radioimmunoassay (RIA) is an immunological assay used to measure the concentration of antigens in vitro.

Application Overview:

By application, the Hospitals segment occupied the biggest share from 2017 to 2022.

Key Companies in the global Bone Metabolism Tests market covered in Chapter 3:

bioMérieux
Maccura Biotechnology
Roche
DiaSorin
Abbott
Snibe
Beckman Coulter
Siemens Healthineers

In Chapter 4 and Chapter 14.2, on the basis of types, the Bone Metabolism Tests market from 2018 to 2029 is primarily split into:

Enzyme-linked Immunosorbent Assay (ELISA)
Chemiluminescence Immunoassay (CLIA)
Radioimmunoassay (RIA)
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Bone Metabolism Tests market from 2018 to 2029 covers:

Hospitals
Reference Laboratories
Specialty Clinics

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)